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Abstract Theaimsof this studyare to characterize thebiological
disease-modifyingantirheumaticdrug(bDMARD)usagepatterns
in real-life and examine the remission rate of rheumatoid arthritis
(RA) patients receiving bDMARDs in routine clinical practice in
China.ConsentingRApatients (≥18years) from15 teaching hos-
pitals and receivingmarketed bDMARDswere included. In total,
802 patients (81.3 % women, 49.0 ± 13.9 years) were included;
89.5%were receiving a combination of bDMARDs and conven-
tional synthetic DMARDs (csDMARDS), whereas 10.5 % were
receiving bDMARD monotherapy. Etanercept (including
Enbrel®and localbrandYiSaiPu®andQiangke®), tocilizumab,
adalimumab, and infliximabwere used by 66.6%, 17.0%, 7.5%,
and 6.6 % patients, respectively. Etanercept was used at a mean
weekly dose of 38.2 ± 15.6 mg for 25.5 ± 47.0 weeks and toci-
lizumab at 94.5 ± 21.9 mg for 4.7 ± 7.5 weeks. Overall rate of
remission was 12.6 %, 5.4 % , and 3.5 % based on DAS28,
CDAI, and SDAI scores, respectively. Compared with patients
receiving bDMARDs for <3 months, those receiving
bDMARDs for ≥3 months exhibited significantly lower DAS28
scores (p< 0.0001), and a significantly higher proportion of pa-
tientswhoreceivedbDMARDsfor≥12monthsachievedthetreat-
ment goal (remission or low disease activity, 62.5 % vs. 18.3 %,
p < 0.0001). Patients receiving combination therapy with
csDMARDs exhibited lower DAS28 scores than patients receiv-
ing bDMARD monotherapy (4.3 vs. 4.8, p = 0.011). This
large-scale real-world study showed that bDMARD usage
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patterns in routine clinical practice in China were in accordance
with internationalguidelines forRAmanagementdespite theshort
treatmentduration.LongerdurationofbDMARDusageandcom-
bination therapy showed a favored outcome of RA.
Keywords Biological . China . DMARD .Duration .
Rheumatoid arthritis . Therapy
Introduction
Rheumatoid arthritis (RA) is a chronic systemic autoimmune
disease associated with progressive joint damage and disabil-
ity. The prevalence of RA is 0.24 % globally and between 0.3
and 1 % in developed countries [1, 2]. In Mainland China, the
prevalence of RA has been reported to be 0.28 % [3, 4]. As
shown by recent studies, RA is becoming one of the most
common disabling and costly disease in China [5–7]. Chou
et al. reported a significantly higher RA prevalence in urban
areas than in rural areas of Taiwan [8]. Socioeconomic and
genetic factors might contribute to the lower prevalence in
China compared with Western countries [9].
Disease-modifying antirheumatic drugs (DMARDs) are the
standard treatment for patients with RA [10]. In addition to con-
ventional syntheticDMARDs (csDMARDs), suchasmethotrex-
ate, biological DMARDs (bDMARDs), including inhibitors
targeting tumor necrosis factor (TNF)-α, T cells, B cells, and
interleukin-6, have been increasingly used in recent years [10,
11]. According to the 2013 European League Against
Rheumatism (EULAR) and the 2012 American College of
Rheumatology (ACR) recommendations, csDMARDs such as
methotrexate should be chosen as the first-line treatment [10,
11]. However, the recommendations suggest bDMARDs for pa-
tientswho fail to achieve lowdisease activity (LDA)or remission
after receiving csDMARDs [10, 11]. Although a combination
therapy of csDMARDs and bDMARDs is recommended and
commonly practiced, real-life registry data show that approxi-
mately 30 % of patients receive bDMARDs as monotherapy in
Western countries [12]. In a double-blind randomized trial,
Dougados et al. found that the efficacy of tocilizumabmonother-
apy was comparable to a combined therapy of tocilizumab plus
methotrexate in patients who had insufficient responses to meth-
otrexate [13]. Emery et al. systematically reviewed trials evaluat-
ing bDMARD monotherapy and found that only tocilizumab
monotherapy appeared to show efficacy equivalent to combina-
tion therapywithmethotrexate [12]. Ina recent largeobservation-
al study, Gabay et al. found that patients receiving tocilizumab
with or without concomitant csDMARD showed comparable
clinical response [14].
Until the end of patient enrollment of this study, a total of six
bDMARDshavebeenapprovedforuseinRAinChina, including
the interleukin-6 receptor inhibitor, tocilizumab, and five TNF
inhibitors (infliximab, adalimumab, and etanercept, including
Enbrel® and local brand Yi Sai Pu® and Qiangke®). In recent
years, bDMARDs have been increasingly prescribed in routine
clinical practice in China. However, the Breal-world^ data on
bDMARDusage patterns in Chinamight be different from those
in developed countries owing to socioeconomic factors. The ob-
jective of this cross-sectional studywas to characterize the usage
patterns of bDMARDs inChinese patientswithRAand examine
the association between disease activity and clinical remission,
andthedurationandpatternofbDMARDtherapy,withthegoal to
optimize themanagement of RA in China.
Materials and methods
Study design
This multicenter observational cross-sectional study was con-
ducted in 15 hospitals across different regions of China. The
study was approved by the Institutional Review Board of
Peking University and independent ethics committees responsi-
ble for each investigating site. The study was conducted in com-
pliance with the Declaration of Helsinki and in accordance with
Good Clinical Practice and relevant ethical guidelines. Written
informed consent was obtained from each participant.
Participants
Patientsaged≥18yearswithconfirmedRAaccordingto theACR
1987 criteria [15] and receiving bDMARDs at the time of inter-
view were enrolled in the study. Patients were excluded if their
physicians believed that the patients were not appropriate to par-
ticipate in the study. Non-consenting patients were excluded.
Data collection
Questionnaires were administered through face-to-face inter-
views in each center by trained participating investigators with
eligible patients. Data on age, sex, RA duration, total joint count,
swollen joint count, and visual analogue scale (VAS) were col-
lected on enrollment visit. The levels of C-reactive protein, he-
moglobin, erythrocyte sedimentation rate, rheumatoid factor,
and anti-cyclic citrullinated peptides measured within 2 weeks
of the enrollment visit were obtained from medical records.
Disease activity was evaluated according to the Disease
Activity Score based on 28-joint count (DAS28) (remission:
DAS28 < 2.6; low disease activity: 2.6 ≤DAS28 < 3.2; moder-
ate disease activity: 3.2 ≤DAS28 < 5.1; high disease activity:
DAS28 ≥ 5.1 [16, 17]), the Simplified Disease Activity Index
(SDAI) (remission: SDAI ≤3.3; low disease activity: 3.3 <
SDAI ≤11; moderate disease activity: 11 < SDAI ≤26; high dis-
ease activity: SADI >26), and the Clinical Disease Activity
Index (CDAI) (remission: CDAI ≤2.8; low disease activity:
2.8 < CDAI ≤10; moderate disease activity: 10 < CDAI ≤22;
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high disease activity: CDAI >22).). Quality of life of patients
was assessed using health assessment questionnaire disability
index (HAQ-DI) on enrollment visit. Visual analog scales on
enrollment visit (from 0 to 10 cm) were used to assess fatigue
and pain levels, with increasing values representingmore severe
fatigue and pain.
Data on usage patterns of bDMARDs, including informa-
tion onmonotherapy or combination therapy, the drug(s) used,
frequency, treatment duration, and dosage of bDMARDs,
were collected. The reasons for discontinuation or switching
of bDMARDs and information about previous bDMARDs,
including drug name and treatment duration, were recorded.
All the AE information of using the common biologic agents
was recorded and followed until return to stabilized.
Sample size estimation
The formula to calculate sample size in a prevalence surveywas
used [18, 19]. Based on European andUS registry data, approx-
imately one third (33 %) of RA patients receive bDMARDs as
monotherapy. Thus, with the assumption that the proportion of
patients in China receiving bDMARD monotherapy is also
33 % and a confidence level of 95 % with maximum relative
error of 10%, the required sample size was estimated to be 800.
Statistical analysis
The statistical analysis was performed using the statistical soft-
ware SAS 9.2 (Cary, North Carolina, USA). Continuous data
are presented as mean and standard deviation (SD), median, and
range. Two-group comparisons were performed using Student t
test (p values were two-sided with a significance level of 0.05).
Multiple-group comparisons were performed by analysis of var-
iance with Bonferroni correction. Laboratory tests performed in
different hospitals were standardized by statistical adjustment
[20]. Categorical data, tabulated as frequencies and percentages,
were analyzed using chi-square test. Missing values were ex-
cluded from the analyses.
Results
Patient characteristics and bDMARD usage patterns
A total of 808 patients were enrolled between December 2013
and August 2014. Six patients were excluded for violating the
inclusion criteria (five patients were diagnosed with ankylos-
ing spondylitis and one patient was <18 years old). Available
data from 802 patients were analyzed. As shown in Table 1,
patients (mean age of 49.0 ± 13.9 years) had a mean disease
course of 3.2 ± 5.8 years. Abnormal C-reactive protein and
erythrocyte sedimentation rate levels were exhibited by 60.8
% and 70.1 % of patients, respectively. The majority of the
patients were positive for rheumatoid factor (77.6 %) or anti-
cyclic citrullinated peptides (83.2 %). Disease activity in the
patients varied widely, as reflected by a broad range of
DAS28, CDAI, and SDAI scores. The patients reported good
quality of life and medium levels of fatigue and pain.
In the current study, etanercept was used by 66.6 % (in-
cluding Yi Sai Pu® 58.1 %, Enbrel® 6.1 %, and Qiangke®
2.4 %) patients. Tocilizumab, adalimumab, and infliximab
were used by 17.0 %, 7.5 %, and 6.6 % of patients, respec-
tively. The mean weekly doses and durations of bDMARDs
are shown in Table 2. Only 10.5 % of patients were receiving
bDMARD monotherapy, amongst who, 75.0 %, 10.7 %, 9.5
%, and 4.8 % were using etanercept, infliximab, tocilizumab,
and adalimumab, respectively. The remaining patients
(89.5 %) were receiving combination therapy of csDMARDs
and bDMARDs. Most patients received one (49.3 %) or two
(41.2 %) csDMARDs, whereas only 9.5 % were on three
csDMARDs. Among the patients on combination therapy, the
proportion of patients using etanercept, infliximab, tocilizumab,
or adalimumab was 65.7 %, 8.4 %, 18.1 %, and 7.8 %, respec-
tively; these proportions were similar to those of patients on
bDMARD monotherapy. The dose and duration of
bDMARDs in combination therapy were comparable to those
in bDMARD monotherapy (Table 3). The most commonly
administered concomitant csDMARD was methotrexate, used
by 65.9% of patients at a mean weekly dose of 9.8 ± 2.8 mg for
63.4 ± 120.8 weeks. Furthermore, 41.8 % and 41.5 % of pa-
tients were using concomitant hydroxychloroquine (2382.1
± 674.1 mg/week) and leflunomide (107.8 ± 36.4 mg/week),
respectively. In addition to csDMARDs, other types of drugs,
including nonsteroidal anti-inflammatory drugs (NSAIDs), glu-
cocorticoids, and topical drugs, were concomitantly used by
56.1 %, 29.7 %, and 19.1 % of patients, respectively (Table 3).
The three top reasons for discontinuing bDMARDs
(n = 58) were clinical improvement (31.0 %), financial burden
(24.1 %), and AEs (13.8 %). Among patients switching to
different bDMARDs (n = 93), the main reasons for switching
were unsatisfactory efficacy of the previous bDMARD
(58.1 %), AEs (14.0 %), improvement of disease condition
(10.8 %), and financial burden (10.8 %). Among the 802
patients, only 5 (0.6%) reported at least one AE after initiation
of this study, including one case of mild pruritus and another
case of rash, which were suspected to be associated with
etanercept. No bDMARDs-related serious AE was reported.
Further analyses of disease activity revealed that the overall
rate of remission was 12.6 %, 5.4 %, and 3.5 % based on
DAS28, CDAI, and SDAI scores, respectively.
Short duration of bDMARD therapy was associated
with poor management of RA
The duration of bDMARD therapy in the patients varied from
0.1 to 350.0 weeks (Table 2). Patients receiving bDMARDs
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for 3.0–5.9 months or for >12 months had significantly lower
DAS28 scores than those receiving bDMARDs <3 months
(p = 0.0002 and p < 0.0001, respectively, Table 4). A signifi-
cantly larger proportion of patients with ≥12 months
bDMARD therapy (DAS28 62.5 %, SDAI 63.6 %, CDAI
62.9 %) achieved treatment target (LDA or remission) com-
pared with patients with <12 months (DAS28 21.0 %, SDAI
15.2%, CDAI 25.8%, all p < 0.05). In contrast, the proportion
of patients achieving treatment target was significantly lower
in patients with <3 months bDMARDs (SDAI 12.2 %, CDAI
Table 1 Patient characteristics
(N = 802) Patients, n (%) Mean (SD) Median (range)




Body weight (kg) 799 58.9 (10.6) 58.0 (30.0–104.0)
RA status
Disease coursea (years) 357 3.2 (5.8) 0.6 (0.0–40.3)
0.0–0.5, n (%) 176 (49.3)
0.5–10, n (%) 139 (38.9)
More than 10, n (%) 42 (11.8)
CRP (mg/mL) 344 27.7 (33.9) 12.7 (0.1–210.0)
Abnormalb, n (%) 209 (60.8)
ESR (mm/hour) 394 42.4 (31.1) 35.5 (1.0–140.0)
Abnormalb, n (%) 276 (70.1)
Hemoglobin (g/L) 411 117.1 (18.8) 118.3 (63.7–165.2)
Anemiac, n (%) 147 (35.8)
RF, n (positive %) 184 (77.6)
ACCP, n (positive %) 144 (83.2)
DAS28 412 4.4 (1.5) 4.4 (0.5–7.7)
CDAI 801 20.2 (15.3) 16.0 (0.0–76.0)
SDAI 343 27.2 (18.1) 23.9 (0.13–83.5)
TJC 802 6.7 (7.2) 4.0 (0.0–28.0)
SJC 802 4.8 (6.1) 2.0 (0.0–28.0)
Quality of life assessment
HAQ-DI 801 11.9 (13.4) 7.0 (0.0–60.0)
VAS-fatigue 801 3.7 (2.5) 3.5 (0.0–10.0)
VAS-pain 801 4.2 (2.4) 4 (0.0–10.0)
SD standard deviation, RA Rheumatoid arthritis, CRP C-reactive protein ESR Erythrocyte sedimentation rate, RF
Rheumatoid factor, ACCPAnti-cyclic citrullinated peptide,DAS28Disease activity score based on 28-joint count,
CDAI Clinical disease activity index, SDAI Simplified disease activity index, TJC Tender joint count, SJC
Swollen joint count, HAQ-DI Health assessment questionnaire disability index, VAS Visual analog scale
a Disease course was calculated according to the following equation: (the date when a patient signed the informed
consent − the data when RAwas diagnosed + 1) / 365.25
b The definitions of abnormal CRP and ESR follow participating hospitals’ standardized criteria
c Anemia was defined as hemoglobin <120 g/L for men and hemoglobin <110 g/L for women
Table 2 Dose and treatment
duration of bDMARD therapy bDMARD Patients, n (%) Weekly dose (mg) Treatment duration (weeks)
Mean (SD) Median (range) Mean (SD) Median (range)
Etanercept 534 (66.6) 38.2 (15.6) 50 (2.1–100.0) 25.5 (47.0) 6.0 (0.1–350.0)
Tocilizumab 136 (17.0) 94.5 (21.9) 100 (30.0–160.0) 4.7 (7.5) 1.0 (0.1–34.0)
Adalimumab 60 (7.5) 20.1 (6.4) 20.0 (5.0–40.0) 12.7 (19.4) 4.0 (0.1–104.0)
Infliximab 53 (6.6) 33.1 (23.6) 25.0 (3.8–100.0) 34.5 (39.1) 24.0 (0.1–186.0)
38 Clin Rheumatol (2017) 36:35–43
19.5 %) than in those with 3.0–5.9 months bDMARDs (SDAI
35.7 %, CDAI 40.7 %, all p < 0.0083, Fig. 1). The proportion
of patients achieving treatment target was not significantly
different between patients with 3–5.9 months bDMARDs
and patients with 6.0–11.9 months (all p > 0.0083, Fig. 1).
The effects of treatment regimen on disease activity
Patients receiving combination therapy of bDMARDs and
csDMARDs showed significantly lower mean DAS28 scores
than patients on bDMARD monotherapy (4.3 vs. 4.8,
p = 0.0108, Table 5). However, the percentage of patients
achieving treatment target was not significantly different
Table 3 bDMARD monotherapy and combination therapy (N = 802)
Therapy type Patients
n (%)
No. of patients with available
therapy duration
Duration (week)
Mean (SD) Median (range)
bDMARD monotherapyb 84 (10.5)a 84 27.4 (54.6) 1.5 (0.1–240.0)
Etanercept 63 (75.0) 63 29.0 (58.2) 1.0 (0.1–240.0)
Infliximab 9 (10.7) 9 42.0 (60.8) 24.0 (0.1–186.0)
Tocilizumab 8 (9.5) 8 8.0 (9.8) 4.1 (0.1–28)
Adalimumab 4 (4.8) 4 7.4 (13.7) 0.8 (0.1–28.0)
bDMARD+ csDMARD combination therapyc 718 (89.5)a 718 21.1 (39.7) 4.4 (0.1–350.0)
Etanercept 472 (65.7) 472 25.0 (45.4) 6.0 (0.1–350.0)
Infliximab 60 (8.4) 60 33.3 (35.3) 23.0 (0.1–165.0)
Tocilizumab 130 (18.1) 130 4.5 (7.3) 1.0 (0.1–34.0)
Adalimumab 56 (7.8) 56 13.1 (19.8) 4.0 (0.1–104.0)
Number of concomitant csDMARDs 718 (100)
One kind of csDMARDs 354 (49.3) NA NA
Two kinds of csDMARDs 296 (41.2) NA NA
Three kinds of csDMARDs 68 (9.5) NA NA
Type of concomitant csDMARDsd 718 (100)
Methotrexate 473 (65.9) 468 63.4 (120.8) 16.0 (0.1–999)
Hydroxychloroquine 300 (41.8) 298 37.3 (58.5) 10.0 (0.1–364.0)
Leflunomide 299 (41.6) 296 59.1 (82.6) 28.0 (0.1–520.0)
Sulfasalazine 46 (6.4) 45 61.3 (148.6) 12.0 (0.1–750.0)
Others 34 (4.7) 32 NA NA
Other concomitant drugs 802 (100) NA NA
Nonsteroidal anti-inflammatory drugs 450 (56.1) NA NA
Glucocorticoidse 238 (29.7) NA NA
Topical drugs 153 (19.1) NA NA
a Percentage was calculated using the total number of patients (N = 802) as the denominator
b bDMARD monotherapy represents bDMARD alone without combination with csDMARDs; the percentage of each bDMARD was calculated using
the total number of patients on monotherapy (n = 84) as the denominator
c bDMARD+ csDMARD combination therapy represents combination of bDMARDs and csDMARDs; the percentage of each bDMARD was calcu-
lated using the total number of patients on combination therapy (n = 718) as the denominator
d The percentage of each type of csDMARDwas calculated using the total number of patients on bDMARD + csDMARD combination therapy (n = 718)
as the denominator
e Among the 238 patients on concomitant glucocorticoids, 73.1 and 23.1 % patients were receiving oral prednisone and methylprednisolone at a mean
(SD) weekly dose (mg) of 57.8 (31.9) and 59.7 (151.6), respectively








0.0–2.9 312 4.6 (1.5)
3.0–5.9 35 3.5 (1.4) 0.0002*
6.0–11.9 25 3.9 (1.4) 0.0945*
>12 40 3.2 (1.4) <0.0001*
*Compared with 0.0–2.9-month group, with analysis of variance follow-
ed by Bonferroni correction. The adjusted α = 0.05/6 = 0.0083;
*p < 0.0083
aNumber of patients with available score data
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between bDMARD monotherapy and combination therapy
(21.4 % vs. 25.6 %, p = 0.507, Table 5). Further examination
of patients with bDMARDmonotherapy revealed that DAS28
score was significantly lower in patients receiving tocilizumab
than in patients receiving TNF inhibitors (3.6 ± 2.1 vs. 5.0
± 1.7, p = 0.0479, Table 5). Consistently, significantly higher
proportion of patients with tocilizumab monotherapy reached
treatment target compared with patients receiving TNF inhib-
itor type of bDMARDs (57.1 % vs. 16.3 %, p = 0.0317,
Table 5). Notably, the DAS28 score in patients receiving
TNF inhibitors as monotherapy was significantly higher than
that in patients receiving combination therapy of TNF inhib-
itors and csDMARDs (5.0 ± 1.7 vs. 4.3 ± 1.4, p = 0.0012,
Table 5), suggesting that TNF inhibitor monotherapy may
not be as effective as combination therapy of TNF inhibitors
plus csDMARDs. In contrast, DAS28 score was not signifi-
cantly different in patients receiving tocilizumabmonotherapy
and patients receiving combination therapy of tocilizumab and
csDMARDs (3.6 ± 2.1 vs. 4.3 ± 1.6, p = 0.2672, Table 5).
Discussion
This is the first large-scale multicenter study to characterize
real-life bDMARD usage patterns and disease activity in rou-
tine practice in Chinese patients with RA receiving
bDMARDs. The results show that combination therapy of
bDMARDs and csDMARDs was substantially more common
than bDMARDmonotherapy in real-world clinical practice in
China. Methotrexate was the predominant csDMARD admin-
istered to Chinese patients. The usage pattern of bDMARDs in
China is in accordance with the guidelines for management of
RA, in which methotrexate is recommended as the first-line
agent and bDMARDs are used as secondary agents, mostly in
combination with csDMARDs [10].
This study found that the proportion of patients receiving
bDMARDmonotherapy in China was only 10.5 %, consider-
ably lower than that in other countries. Yazici et al. investigat-
ed the RA patient cohort in the Thomson Healthcare
MarketScan Research databases and found that 30 % of adults
with RA received bDMARD monotherapy in the USA [19].
Gabay et al. examined the data from the Swiss Clinical
Quality Management in Rheumatic Diseases registry for RA
patients and found that bDMARD monotherapy was pre-
scribed for up to 39 % of treatment courses [21]. Kaufmann
Fig. 1 The proportion of patients achieving treatment goal with various
durations of bDMARDs. Comparison was performed by multiple
comparisons with Bonferroni adjustments (the adjusted α = 0.05/
6 = 0.0083; *p < 0.0083)
Table 5 The effects of treatment
type on DAS28 score and




p value Remission + LDA
rate (%)
p value
bDMARD therapy 412 (total)
bDMARD monotherapy 56 4.8 (1.8) 0.0108 21.4 0.507
bDMARD combination therapy 356 4.3 (1.5) 25.6
bDMARD monotherapy 56 (total)
TNF inhibitorsb 49 5.0 (1.7) 0.0479 16.3 0.0317
Tocilizumab 7 3.6 (2.1) 57.1
TNF inhibitorsb 327
Monotherapy 49 5.0 (1.7) 0.0012
Combination therapy 278 4.3 (1.4)
Tocilizumab 85
Monotherapy 7 3.6 (2.1) 0.2672
Combination therapy 78 4.3 (1.6)
a Number of patients with available score data
b TNF inhibitors include infliximab, adalimumab, and etanercept
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et al. conducted a retrospective study of 254 German patients
and found that between 18% and 41% of patients treated with
bDMARDs received the agent as monotherapy [22].
Overall, disease control in our patient cohort was not opti-
mal despite the use of bDMARDs. The majority (75 %) of
patients were classified as having moderate- or high-disease
activity per DAS28 scores. The substantially shorter mean
treatment duration of bDMARD therapy (4.7–34.5 weeks) in
our study population versus that shown in other studies [23,
24] may be responsible for the suboptimal remission rates that
we observed. The mean duration of treatment with etanercept,
adalimumab, and infliximab in Italian patients with RA from
the Italian Group for the Study of Early Arthritis registry was
3.1, 2.6, and 2.7 years, respectively [23]. Patients with RA
from the Swiss Clinical Quality Management in Rheumatic
Diseases registry received anti-TNF therapy for a median du-
ration of 37 months [24]. The possible reason for the short
treatment duration in the Chinese patients in the current study
may be associated with poor socioeconomic condition, poor
patient compliance, and the limitation of cross-sectional study.
bDMARDs are relatively expensive and are not covered by
the national health insurance reimbursement policies in China.
This study demonstrated that the proportion of remission +
LDAwas the highest in patients with ≥12months of treatment,
indicating that long-time treatment maximizes the benefits for
patients. These results are in line with those of a previous 4-
year follow-up study of infliximab therapy in refractory RA
patients, which showed that longer duration of infliximab
therapy resulted in lower DAS28 score [25]. Nam et al. found
that maintenance of clinical responses was higher with
bDMARD continuation [26]. Thus, our results suggest that,
to achieve the best treatment outcome, patients with RA
should continue bDMARD therapy for longer than 12months.
Furthermore, this study revealed that the remission rate in
Chinese patients receiving bDMARDs was 12.6 %
(DAS28), 5.4 % (CDAI), and 3.5 % (SDAI). In a multicenter
cross-sectional study of RA in Chinese patients receiving
csDMARDs, bDMARDs, and/or glucocorticoids, Wang
et al. found the remission rate to be 8.6 % (DAS28), 8.2 %
(CDAI), 8.4 % (SDAI), and 6.8 % (Boolean) [27]. In Qatari,
the remission rate of patients with RA receiving bDMARDs
and/or csDMARDs was 49 % by DAS28 score [28]. In the
QUEST-RA study including patients with RA from 25 mostly
European countries, remission rate was 13.8 % and 19.6 % by
CDAI and DAS28, respectively [29]. These results indicate
that treatment for Chinese patients with RA is insufficient.
Further, the inhibitory costs of biologics ($15,000–$25,000
per patient per year) [30] present challenges in developing
countries [31] and may result in early treatment discontinua-
tion or dose reduction, resulting in flaring of the disease.
While the guidelines do not recommend treatment discontin-
uation, Bstep-down^ or tapering strategies by careful dose
reduction or injection spacing can maintain a disease-free
status in patients who have achieved remission or low disease
activity [32]. Studies have shown that patients in remission
after bDMARD mono or combination therapy continued to
maintain their remission status after careful dose tapering or
treatment discontinuation [33, 34]. Further, in order to main-
tain the alleviating effect, the dose of traditional DMARDS
may be increased or treatment options such as double and
triple combination treatment may be prescribed. Therapy can
be reinitiated when necessary, making this approach desirable
from a safety viewpoint and curbing unnecessary healthcare
expenditure. Careful patient selection based on clinical and
practical considerationsmay also improve outcomeswith con-
tinuous bDMARD use in the developing world.
The current RA management regimen in China should be
optimized to allow patients to benefit from more aggressive
treatment. Given the comparable efficacy and cost-
effectiveness of triple DMARD combinations in comparison
with bDMARDs and methotrexate [35, 36], further studies are
needed to assess the use of triple DMARD combination ther-
apy in comparison with biologics in China.
Although the 2013 EULAR guidelines for RA manage-
ment recommend bDMARDs to be used concomitantly with
csDMARDs [10], the 2015 ACR guidelines take monothera-
py into consideration [37] and bDMARDs monotherapy is
also used in clinical practice as needed [12]. In some studies,
bDMARD monotherapy has been shown to be as effective as
the combination therapy of csDMARDs and bDMARDs. In
terms of DAS28 score, ACR responses, and swollen and ten-
der joint counts, tocilizumab and methotrexate combination
therapy was not superior to tocilizumab monotherapy [13,
38]. Consistently, the current study also demonstrated that
DAS28 score in patients receiving tocilizumab monotherapy
was similar to that in patients receiving tocilizumab and
csDMARD combination therapy. In the current study, al-
though the average DAS28 score was significantly higher in
patients receiving bDMARD monotherapy than in patients
receiving combination therapy, the rate of reaching treatment
target was similar in patients receiving monotherapy versus
combination therapy. Interestingly, the current study found
that patients with tocilizumab monotherapy showed signifi-
cantly lower DAS28 score and higher proportion of reaching
treatment target than patients receiving other types of
bDMARD monotherapy. These findings suggest that toci-
lizumab monotherapy may be a promising option for patients
with RA. Simplification and optimization of the treatment for
RA are beneficial for both patients and physicians.
This cross-sectional study design presents a Bsnapshot^ of
bDMARD usage in Chinese patients with RA. It is difficult to
infer causal relationships between bDMARD usage pattern
and disease activity of RA, although longer duration of
bDMARD therapy was associated with lower DAS28 score
and higher rate of achievement of treatment goal through ad
hoc analysis. Confounding factors that might affect the
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relationship between duration of bDMARD therapy and dis-
ease activity, such as the disease status prior to receiving
bDMARD therapy and other concomitant therapies, were
not considered in this study.
In conclusion, the usage of bDMARDs in Chinese patients
with RA is in accordance with the global recommendations
despite the short treatment duration. The bDMARDs are com-
monly used in combination with csDMARDs. Longer dura-
tion of bDMARD therapy appears to be associated with lower
DAS28 scores and higher proportion of achievement of treat-
ment target. These results should be kept in mind by the cli-
nicians while treating patients with RAwho do not achieve the
treatment goal within 3 to 6 months of therapy. To achieve the
best treatment outcome, patients with RA should continue
bDMARD therapy for longer than 12 months. Our results
provide a strong evidence base for the government to make
decisions for the benefit of a greater number of patients with
RA. Tocilizumab monotherapy may be a promising option for
patients with RA. Further prospective studies are needed to
assess the impact of bDMARDusage on RA remission among
the Chinese population.
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